Savara Inc. (SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, is progressing toward a key regulatory milestone for its lead investigational asset, MOLBREEVI.
MOLBREEVI is a non-glycosylated form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in inhaled formulation being developed as a potential treatment option for autoimmune pulmonary alveolar proteinosis (aPAP).
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.